Nuclear medicine

Oxford Handbook of Clinical and Laboratory Investigation ◽

10.1093/med/9780199233717.003.0014 ◽

2010 ◽

pp. 793-856

Keyword(s):

Bone Marrow ◽

Nuclear Medicine ◽

Bone Scan ◽

Somatostatin Receptor ◽

Reticuloendothelial System ◽

Csf Shunt ◽

Parathyroid Scintigraphy ◽

Thyroid Scintigraphy ◽

Blood Flow Imaging ◽

Receptor Scintigraphy

Introduction to nuclear medicine 794 Bone scintigraphy: bone scan 796 Reticuloendothelial system: bone marrow scintigraphy 798 Cerebral blood flow imaging 800 Brain transporter imaging 802 CSF shunt patency 804 Thyroid scintigraphy 806 Parathyroid scintigraphy 808 Metaiodobenzylguanidine imaging 809 Somatostatin receptor scintigraphy 812 Radioiodine thyroid cancer imaging ...

Download Full-text

Mack Forster Award Lecture Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients

European Journal of Clinical Investigation ◽

10.1046/j.1365-2362.1997.1990742.x ◽

1997 ◽

Vol 27 (10) ◽

pp. 793-800 ◽

Cited By ~ 25

Author(s):

I. VIRGOLINI

Keyword(s):

Nuclear Medicine ◽

Somatostatin Receptor ◽

Somatostatin Receptor Scintigraphy ◽

Diagnosis And Treatment ◽

Receptor Scintigraphy

Download Full-text

Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd

Medical Radiology and radiation safety ◽

10.12737/1024-6177-2020-65-2-44-49 ◽

2020 ◽

Vol 65 (2) ◽

pp. 44-49

Author(s):

K. Slashchuk ◽

P. Rumyantsev ◽

M. Degtyarev ◽

S. Serzhenko ◽

O. Baranova ◽

...

Keyword(s):

Nuclear Medicine ◽

Neuroendocrine Tumors ◽

Somatostatin Receptor ◽

Somatostatin Receptors ◽

Diagnostic Value ◽

Radioactive Isotopes ◽

Topical Diagnosis ◽

Pet Ct ◽

Receptor Scintigraphy ◽

Pet Ct Scan

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms constituting about 0.5 % of all cancer cases. In recent years, there has been a significant increase in the incidence of NETs, which is primarily due to the active development and improvement of medical imaging technologies. Successful treatment and prognosis for patients with NETs strongly depend on the stage of the disease. One of the effective methods of visualization and staging NETs in nuclear medicine is somatostin receptor scintigraphy (SRS), which is based on the use of partial somatostatin receptor agonists labeled with radioactive isotopes. The article presents an analysis of 55 patients with NETs of various localizations who underwent scintigraphy and SPECT/CT. Radiopharmaceutical was used as a tracer for SRS. It was prepared on the basis of a lyophilisate developed by Polatom (Poland) — Tektrotyd, labeled with 99mTc. According to the results of the study SRS with 99mTc-Tektrotyd is informative in the topical diagnosis of NETs, especially when PET/CT scan with 68Ga-labeled peptides is not available. Sensitivity varies depending on the NET localization. It is necessary to continue researches on the diagnostic value of SRS with 99mTc-Tektrotyd for tumors, in the pathogenesis of which somatostatin receptors play a significant role.

Download Full-text

Assessment of endocrine disorders of the hypothalamicpituitary axis by nuclear medicine techniques

Nuklearmedizin ◽

10.1055/s-0038-1625645 ◽

2002 ◽

Vol 41 (02) ◽

pp. 80-90 ◽

Cited By ~ 2

Author(s):

F. Jockenhövel ◽

P. Theissen ◽

M. Dietlein ◽

W. Krone ◽

H. Schicha ◽

...

Keyword(s):

Nuclear Medicine ◽

Pituitary Adenomas ◽

Dopamine D2 Receptor ◽

Somatostatin Receptor ◽

D2 Receptor ◽

Ectopic Acth Syndrome ◽

Endocrine Disorders ◽

Ectopic Acth ◽

Number Of Patients ◽

Hypothalamic Pituitary Axis

SummaryThe following article reviews nuclear medicine techniques which can be used for assessment of endocrine disorders of the hypothalamic-pituitary axis. For planar and SPECT imaging somatostatin-receptor- and dopamine- D2-receptor-scintigraphy are the most widely distributed techniques. These nuclear medicine techniques may be indicated in selected cases to answer differential diagnostic problems. They can be helpful to search for presence and localization of receptor positive tissue. Furthermore they can detect metastasis in the rare cases of a pituitary carcinoma. Scintigraphy with Gallium-67 is suitable for further diagnostic evaluation in suspected hypophysitis. Other SPECT radiopharmaca do not have relevant clinical significance. F-18-FDG as PET radiopharmacon is not ideal because obvious pituitary adenomas could not be visualized. Other PET radiopharmaca including C-11-methionine, C-11-tyrosine, F-18-fluoroethylspiperone, C-11-methylspiperone, and C-11-raclopride are available in specialized centers only. Overall indications for nuclear medicine in studies for the assessment of endocrine disorders of the hypothalamic-pituitary-axis are rare. Original studies often report only about a small number of patients. According to the authors’ opinion the relevance of nuclear medicine in studies of clinically important endocrinologic fields, e. g. localization of small ACTH-producing pituitary adenomas, tumor localization in ectopic ACTH syndrome, localization of recurrent pituitary tissue, assessment of small incidentalomas, can not be definitely given yet.

Download Full-text